| Name | Title | Contact Details |
|---|
StemoniX microHeart® products in high density plate formats provide researchers with structurally aligned cardiac cells resembling native human heart tissue with accelerated features of cell maturity.
CoDa Therapeutics is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EpiVax Oncology is developing precision cancer immunotherapies based on mutanome-directed neo-epitopes, selected using proprietary and validated in silico predictive algorithms. Neo-epitopes are mutated and tumor specific epitopes, recognized as non-self, capable of generating highly potent specific T cell immunogenic responses against tumors, translating in improved clinical outcome. EpiVax Oncology is developing neo-epitope based therapeutic vaccines customized and specifically designed for each cancer patient, based on the genetic profiling (using next generation DNA sequencing) of each patient`s unique tumor and normal genome sequence (the mutanome). EpiVax Oncology`s ultimate purpose is to address major unmet medical needs inadequately addressed by other oncology and immuno-oncology treatments which are either only benefiting a very limited subset of patients, or prone to adverse events, or extremely costly and complex to manufacture. EpiVax Oncology`s ambition is to become a premier cancer precision medicine company, leveraging EpiVax`s world class excellence in computational-immunology, genomics and vaccine design, built over the last 20 years.
Genpathway, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Castle Creek Biosciences, Inc. is a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options. The company`s proprietary autologous fibroblast platform potentially allows for the development of personalized, targeted and redosable cell-based gene therapy product candidates for monogenic and chronic disorders. The company`s most advanced product candidate, dabocemagene autoficel (D-Fi), is currently being evaluated in a Phase 3 clinical trial for the localized treatment of chronic wounds due to recessive dystrophic epidermolysis bullosa (RDEB). The company is also currently evaluating FCX-013 in a Phase 1/2 clinical trial for the treatment of moderate to severe localized scleroderma. In addition, Castle Creek Biosciences is pursuing discovery and potential development of early-stage novel product candidates with the goal of expanding its robust pipeline into other rare diseases and broader indications where there are significant unmet needs. The company operates an in-house, commercial-scale manufacturing facility in Exton, Pennsylvania that benefits from the validated systems and processes previously implemented at the site for manufacture of an FDA-approved cell therapy product. Castle Creek Biosciences, Inc. is a portfolio company of Paragon Biosciences, LLC.